DaVita Inc. Reports Strong Third‑Quarter Results
DaVita Inc. (NYSE: DVA) released its financial results for the quarter ended September 30 2026, reporting a notable increase in earnings and revenue compared with the same period last year.
Key Financial Highlights
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Consolidated revenue | $3.578 billion | $3.420 billion | +4.6 % |
| Net earnings (GAAP) | $222.931 million | $150.332 million | +48.8 % |
| Diluted earnings per share (EPS) | $3.40 | $2.04 | +67.6 % |
| Adjusted earnings | $250 million | – | – |
| Adjusted EPS | $3.82 | – | – |
| Operating income | $499 million | – | – |
| Adjusted operating income | $561 million | – | – |
| Operating cash flow | $519 million | – | – |
| Free cash flow | $276 million | – | – |
DaVita also repurchased 0.6 million shares of its common stock during the quarter at an average price of $186.21 per share.
Guidance and Analyst Expectations
DaVita’s full‑year earnings‑per‑share guidance ranges from $14.30 to $15.20. Analyst consensus for the full fiscal year averages $14.82, while analysts projected a Q3 EPS of $3.57, compared with $2.04 in the same quarter a year earlier.
Community Health Initiative
In addition to its financial performance, DaVita expanded its preventive health outreach by conducting free community health screenings for nearly 1,000 individuals across Greater Houston and Los Angeles. The program aims to identify hidden health risks in underserved populations.
Market Context
As of October 27 2026, DaVita’s share price closed at $183.93. The stock’s 52‑week high and low are $247.49 and $101, respectively. With a market capitalization of approximately $11.68 billion and a price‑earnings ratio of 15.42, the company remains a prominent provider of dialysis services within the health‑care sector.
